Pressmeddelanden från AstraZeneca

Gefurulimab demonstrates statistically significant, clinically meaningful improvement in MG-ADL at week 26, clinically meaningful improvement as early as week one in gMG adults in PREVAIL PhIII trial

Trial met all secondary endpoints including change from baseline in quantitative myasthenia gravis total score at week four and week 26.

Cision • I förrgår 17:31

Alexion data presented at 2025 AANEM Annual Meeting and MGFA Scientific Session underscores pioneering C5 inhibition leadership in gMG

New data on gefurulimab, a novel dual-binding nanobody, from the PREVAIL Phase III trial will highlight its potential as an effective, self-...

Cision • 29 Oct 19:02

Koselugo approved in the EU for plexiform neurofibromas in adults with neurofibromatosis type 1

Approval based on KOMET Phase III trial results which showed 20% objective response rate in tumour size reduction.

Cision • 28 Oct 08:00

Tezspire approved in the EU for chronic rhinosinusitis with nasal polyps

Approval based on WAYPOINT Phase III results demonstrating reduced nasal polyp severity and nasal congestion, near-elimination of the need f...

Cision • 22 Oct 08:01

Tezspire approved in the US for chronic rhinosinusitis with nasal polyps

Approval broadens indication for Tezspire to a second disease characterised by epithelial-driven inflammation.

Cision • 20 Oct 08:19

Saphnelo subcutaneous self-administration recommended for approval in EU by CHMP for systemic lupus erythematosus

Recommendation based on TULIP-SC Phase III trial results showing first-in-class Saphnelo reduced disease activity via once-weekly subcutaneo...

Cision • 20 Oct 08:06

Datroway demonstrated an unprecedented median OS improvement of five months vs. chemotherapy for patients with metastatic TNBC for whom immunotherapy was not an option in TROPION-Breast02

AstraZeneca and Daiichi Sankyo’s Datroway also demonstrated a highly statistically significant and clinically meaningful 43% reduction in pa...

Cision • 19 Oct 08:35

Enhertu reduced the risk of disease recurrence or death by 53% vs. T-DM1 in patients with high-risk HER2-positive early breast cancer following neoadjuvant therapy in DESTINY-Breast05 Phase III trial

More than 92% of patients treated with AstraZeneca and Daiichi Sankyo’s Enhertu were free of invasive disease at three years.

Cision • 18 Oct 16:35

Enhertu followed by THP before surgery resulted in a pathologic complete response in 67% of patients with high-risk HER2-positive early-stage breast cancer in DESTINY-Breast11 Phase III trial

Highest reported pathologic complete response rate seen in a Phase III registrational trial for HER2-positive early breast cancer with favou...

Cision • 18 Oct 16:30

Imfinzi regimen reduced the risk of disease recurrence or death by 32% in high-risk non-muscle-invasive bladder cancer in the POTOMAC Phase III trial

Adding one year of Imfinzi treatment to Bacillus Calmette-Guérin (BCG) induction and maintenance therapy delivered an early and sustained di...

Cision • 17 Oct 14:25

Imfinzi-based regimen reduced the risk of death by 22% in early gastric cancer vs. chemotherapy alone in MATTERHORN Phase III trial

More than two thirds of patients treated with Imfinzi-based perioperative regimen were alive at three years.

Cision • 17 Oct 14:10

AstraZeneca furthers ambition to redefine cancer care with first data from four major pivotal trials at ESMO

Presidential Symposium will feature DESTINY-Breast11 and DESTINY-Breast05, underscoring potential of Enhertu in HER2-positive early breast c...

Cision • 13 Oct 08:06

AstraZeneca announces historic agreement with US Government to lower the cost of medicines for American patients

Delivers on all four of President Trump’s requests reducing cost of medicines.

Cision • 13 Oct 08:01

AstraZeneca plans to increase investment and scope of its Virginia manufacturing facility to $4.5 billion, creating 3,600 new jobs

New manufacturing facility to be located near Charlottesville, in Albemarle County, Virginia will develop and manufacture a broader range of...

Cision • 09 Oct 18:33

Baxdrostat met the primary endpoint in Bax24 Phase III trial in patients with resistant hypertension

Baxdrostat demonstrated a statistically significant and highly clinically meaningful reduction in 24-hour ambulatory systolic blood pressure...

Cision • 07 Oct 08:00

Datroway improved OS and PFS in TROPION-Breast02

Datroway demonstrated statistically significant and clinically meaningful improvement in overall survival as 1st-line therapy for patients w...

Cision • 06 Oct 08:33

Enhertu improved IDFS in early BC in DB-05

Second positive Phase III trial of AstraZeneca and Daiichi Sankyo’s Enhertu in HER2-positive early breast cancer reinforces its potential to...

Cision • 29 Sep 08:30

AstraZeneca to harmonise its listing structure across the London Stock Exchange, Nasdaq Stockholm and New York Stock Exchange

Harmonisation of listing structure requires a direct listing of AstraZeneca shares on the NYSE in place of existing US ADRs.

Cision • 29 Sep 08:02

Enhertu plus pertuzumab granted Priority Review in the US as 1st-line treatment for patients with HER2-positive metastatic breast cancer

Based on DESTINY-Breast09 Phase III trial results which showed Enhertu plus pertuzumab reduced the risk of disease progression or death by 4...

Cision • 24 Sep 08:09

Koselugo recommended for approval in the EU by CHMP for plexiform neurofibromas in adults with neurofibromatosis type 1

Recommendation based on KOMET Phase III trial results which showed 20% objective response rate in tumour size reduction.

Cision • 22 Sep 08:08

Tezspire recommended for approval in the EU by CHMP for chronic rhinosinusitis with nasal polyps

Recommendation based on WAYPOINT Phase III trial results showing Tezspire reduced nasal polyp severity and nasal congestion, nearly eliminat...

Cision • 22 Sep 08:00

Alexion data presented at ECTRIMS 2025 reinforces Ultomiris leadership in transforming care for patients with NMOSD

Final results of CHAMPION-NMOSD Phase III trial long-term extension will show zero relapses in patients on Ultomiris through a median follow...

Cision • 19 Sep 08:00

Saphnelo self-administration TULIP-SC Phase III trial meets primary endpoint in patients with systemic lupus erythematosus based on an interim analysis

Subcutaneous administration of first-in-class biologic Saphnelo demonstrates statistically significant and clinically meaningful reduction i...

Cision • 17 Sep 08:06

Update on the RESOLUTE Phase III trial for Fasenra in chronic obstructive pulmonary disease

Cision • 17 Sep 08:02

Tagrisso plus chemotherapy demonstrated a median overall survival of nearly four years, the longest benefit ever reported in a global Phase III trial in EGFR-mutated advanced lung cancer

FLAURA2 final overall survival analysis reinforces the favourable benefit-risk profile of this combination.

Cision • 07 Sep 08:16

Baxdrostat demonstrated statistically significant and clinically meaningful reduction in systolic blood pressure in patients with hard-to-control hypertension in the BaxHTN Phase III trial

Baxdrostat 2mg lowered systolic blood pressure by 15.

Cision • 30 Aug 16:16

Resultat för AstraZeneca: första halvåret samt andra kvartalet 2025

Den starka tillväxttakten fortsätter med en utmärkt leverans av forskningsportföljen hittills under året

Cision • 29 Jul 08:00

Imfinzi granted Priority Review and Breakthrough Therapy Designation in the US for patients with resectable early-stage gastric and gastroesophageal junction cancers

Based on MATTERHORN Phase III trial results which demonstrated a statistically significant and clinically meaningful event-free survival ben...

Cision • 28 Jul 08:03

Trixeo Aerosphere receives positive EU CHMP opinion as first inhaled medicine using next-generation propellant with near-zero Global Warming Potential

Next-generation propellant offers 99.9% reduction in Global Warming Potential compared to current propellants.

Cision • 25 Jul 12:50

Gefurulimab nanobody met Phase III endpoints

Gefurulimab dual-binding nanobody demonstrated statistically significant and clinically meaningful improvement in functional activities of d...

Cision • 24 Jul 08:05

AstraZeneca plans to invest $50 billion in America for medicines manufacturing and R&D

Investment will support AstraZeneca’s ambition to reach $80 billion revenue by 2030, with 50% generated in the US.

Cision • 22 Jul 08:02

Tagrisso plus chemotherapy demonstrated statistically significant and clinically meaningful improvement in overall survival in EGFR-mutated advanced lung cancer

Longer-term follow up in the FLAURA2 Phase III trial confirms the favourable benefit-risk profile of this combination.

Cision • 21 Jul 08:07

Update on CARES Phase III clinical programme of anselamimab in light chain amyloidosis

Results did not achieve statistical significance for the primary endpoint in overall patient population.

Cision • 16 Jul 08:05

Baxdrostat met the primary and all secondary endpoints in BaxHTN Phase III trial in patients with uncontrolled or treatment resistant hypertension

Baxdrostat demonstrated a statistically significant and clinically meaningful reduction of systolic blood pressure compared with placebo.

Cision • 14 Jul 08:09

Imfinzi approved in the EU as first and only perioperative immunotherapy for muscle-invasive bladder cancer

Approval based on NIAGARA Phase III trial results which showed a 32% reduction in the risk of recurrence and a 25% reduction in the risk of ...

Cision • 04 Jul 08:03

Datroway approved in the US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer

Based on TROPION-Lung05 results and supported by data from TROPION-Lung01.

Cision • 24 Jun 08:01

Alexion data presented at EAN 2025 highlights its leadership and commitment to improving patient outcomes in rare neurological diseases

Data show reduction in steroid burden and event-related hospitalisations in adult patients with AChR-Ab+ gMG treated with Ultomiris (ravuliz...

Cision • 23 Jun 08:04

AstraZeneca enters strategic collaboration with CSPC Pharmaceuticals focused on AI-enabled research

Cision • 13 Jun 10:30

Fixed-duration -based regimens approved in EU for patients with chronic lymphocytic leukaemia in the 1st-line setting

AMPLIFY Phase III trial results demonstrated statistically significant and clinically meaningful improvement in progression-free survival fo...

Cision • 06 Jun 08:03

Enhertu plus pertuzumab reduced the risk of disease progression or death by 44% vs. THP as 1st-line therapy in patients with HER2-positive metastatic breast cancer in DESTINY-Breast09 Phase III trial

AstraZeneca and Daiichi Sankyo’s Enhertu plus pertuzumab showed a median progression-free survival greater than three years.

Cision • 02 Jun 14:06

Imfinzi regimen reduced risk of progression, recurrence or death by 29% in early-stage gastric cancer vs. chemotherapy alone in MATTERHORN Phase III trial

Two-thirds (67.4%) of patients treated with Imfinzi-based perioperative regimen remained event-free at two years.

Cision • 01 Jun 14:05

Camizestrant reduced the risk of disease progression or death by 56% in patients with advanced HR-positive breast cancer with an emergent ESR1 tumour mutation in SERENA-6 Phase III trial

First pivotal trial to demonstrate clinical value of monitoring circulating tumour DNA to detect and treat emerging resistance in 1st-line t...

Cision • 01 Jun 14:00

Imfinzi recommended for approval in the EU by CHMP as first and only perioperative immunotherapy for muscle-invasive bladder cancer

Recommendation based on NIAGARA Phase III trial results which showed a 32% reduction in the risk of recurrence and a 25% reduction in the ri...

Cision • 27 May 08:01

AstraZeneca’s record seventh year of plenary data at ASCO furthers ambition to redefine breast cancer care and transform outcomes in gastric cancer

SERENA-6 plenary presentation will feature next-generation oral SERD camizestrant in 1st-line advanced HR-positive breast cancer.

Cision • 21 May 08:00

Acquisition of EsoBiotec completed

Cision • 20 May 08:07

Statistically significant and clinically meaningful BATURA Phase III trial results provide new evidence for Airsupra as standard of care for as-needed rescue treatment in asthma

Airsupra demonstrated a 47% reduction in the risk of severe exacerbations in mild asthma compared with albuterol alone.

Cision • 19 May 18:18

AstraZeneca to showcase latest research on comprehensive portfolio and pipeline aimed at transforming respiratory diseases at ATS 2025

New data for Airsupra and Breztri highlight progress in advancing asthma and COPD care globally.

Cision • 13 May 08:01

Trixeo Aerosphere approved in the UK as first inhaled respiratory medicine using next-generation propellant with near-zero Global Warming Potential

Next-generation propellant offers 99.9% reduction in Global Warming Potential compared to current propellant.

Cision • 12 May 08:05

Imfinzi regimen demonstrated statistically significant and clinically meaningful improvement in disease-free survival for high-risk non-muscle-invasive bladder cancer in POTOMAC Phase III trial

Patients lived significantly longer without high-risk disease recurrence or progression after one year of Imfinzi treatment plus Bacillus Ca...

Cision • 09 May 08:00

Enhertu improved pCR in early-stage breast cancer

AstraZeneca and Daiichi Sankyo’s Enhertu followed by THP showed an improved safety profile vs.

Cision • 07 May 08:30

Calquence plus chemoimmunotherapy approved in the EU as first and only BTK inhibitor for 1st-line mantle cell lymphoma

Approval based on ECHO Phase III trial results which demonstrated over 16 months of progression-free survival improvement vs.

Cision • 06 May 08:04

Breztri met primary endpoints in KALOS and LOGOS Phase III trials in asthma

Positive high-level results from the Phase III KALOS and LOGOS trials in patients with uncontrolled asthma showed that AstraZeneca’s fixed-d...

Cision • 02 May 08:05

Fixed-duration -based regimens recommended for approval in the EU by CHMP for 1st-line chronic lymphocytic leukaemia

Recommendation based on AMPLIFY Phase III trial which showed Calquence combinations demonstrated statistically significant and clinically me...

Cision • 29 Apr 08:10

Update on CAPItello-280 Phase III trial of Truqap in metastatic castration-resistant prostate cancer

Cision • 29 Apr 08:05

Resultat för AstraZeneca: Q1 2025

Cision • 29 Apr 08:00

Enhertu combination improved PFS in 1L HER2+ mBC

DESTINY-Breast09 Phase III trial of AstraZeneca and Daiichi Sankyo’s Enhertu is the first trial in more than a decade to demonstrate superio...

Cision • 22 Apr 08:00

Results of Annual General Meeting held on 11 April 2025

Cision • 11 Apr 18:30

AstraZeneca showcases innovation in infectious disease protection at ESCMID Global 2025

Data highlight ambition to transform prevention and treatment for serious bacterial infections and develop novel preventative strategies for...

Cision • 08 Apr 08:01

Imfinzi-based perioperative regimen approved in the EU for resectable non-small cell lung cancer

Approval based on AEGEAN Phase III trial results which showed a 32% reduction in the risk of recurrence, progression or death vs.

Cision • 04 Apr 08:06

Enhertu approved in the EU as first HER2-directed therapy for patients with HR-positive, HER2-low or HER2-ultralow metastatic breast cancer following at least one endocrine therapy

Based on DESTINY-Breast06 Phase III trial results which showed Enhertu demonstrated superiority vs.

Cision • 04 Apr 08:03

AZD0780, a novel oral PCSK9 inhibitor, demonstrated significant LDL cholesterol (LDL-C) reduction in PURSUIT Phase IIb trial

New late-breaking clinical trial data presented at ACC and published simultaneously in JACC show benefit of investigational medicine AZD0780...

Cision • 31 Mar 18:05

Calquence plus chemoimmunotherapy recommended for approval in the EU by CHMP as first and only BTK inhibitor for 1st-line mantle cell lymphoma

Recommendation based on ECHO Phase III trial results which demonstrated over 16 months of progression free survival improvement vs.

Cision • 31 Mar 08:13

Imfinzi approved in the US as first and only perioperative immunotherapy for patients with muscle-invasive bladder cancer

Based on NIAGARA Phase III trial results which showed a 32% reduction in the risk of recurrence and a 25% reduction in the risk of death vs.

Cision • 31 Mar 08:06

Alexion data presented at the 2025 AAN Annual Meeting highlight advancements in improving care for rare neurological diseases

Clinical and real-world evidence will reinforce the long-term safety profile and sustained efficacy of Ultomiris and Soliris in NMOSD and gM...

Cision • 27 Mar 08:06

New study results reinforce Tagrisso as the backbone therapy for EGFR-mutated lung cancer across stages and settings

In LAURA Phase III trial, Tagrisso continues to demonstrate improved overall survival trend in unresectable, Stage III setting.

Cision • 25 Mar 08:05

AstraZeneca to invest $2.5 billion in new global strategic R&D centre, biotech agreements and manufacturing in Beijing

AstraZeneca is establishing a new global strategic R&D centre in Beijing, its second in China and sixth worldwide.

Cision • 21 Mar 12:09

AstraZeneca enters license agreement with Alteogen for subcutaneous formulations of multiple oncology assets

Cision • 17 Mar 08:26

Eneboparatide met primary endpoint of normalising serum calcium in adults with hypoparathyroidism at 24 weeks in CALYPSO Phase III trial

Trial continues as planned to 52 weeks to further characterise the risk-benefit profile.

Cision • 17 Mar 08:20

Imfinzi approved in the EU as first and only immunotherapy for limited-stage small cell lung cancer

Approval based on ADRIATIC Phase III trial results which showed a 27% reduction in the risk of death versus placebo.

Cision • 17 Mar 08:12

AstraZeneca to acquire EsoBiotec to advance cell therapy ambition

Acquisition includes world-leading in vivo delivery platform with potential to transform cell therapy.

Cision • 17 Mar 08:03

Notice of Annual General Meeting

Cision • 07 Mar 12:00

Imfinzi-based regimen demonstrated statistically significant and clinically meaningful improvement in event-free survival in resectable early-stage gastric and gastroesophageal junction cancers

MATTERHORN is first global, randomised Phase III trial to demonstrate superior event-free survival with an immunotherapy combination over st...

Cision • 07 Mar 08:02

Imfinzi-based perioperative regimen recommended for approval in the EU by CHMP for resectable non-small cell lung cancer

Recommendation based on AEGEAN Phase III trial results which showed Imfinzi reduced the risk of recurrence, progression or death by 32% vs.

Cision • 03 Mar 08:06

Positive results from the Tezspire Phase III WAYPOINT trial highlight rapid and sustained effect in chronic rhinosinusitis with nasal polyps

Tezspire significantly reduced nasal congestion, polyp size and nearly eliminated the need for surgery in patients with chronic rhinosinusit...

Cision • 02 Mar 08:00

Enhertu recommended for approval in the EU by CHMP for patients with HER2-low or HER2-ultralow metastatic breast cancer following at least one endocrine therapy

Recommendation based on DESTINY-Breast06 Phase III trial results which showed Enhertu demonstrated superiority vs.

Cision • 28 Feb 14:00

Camizestrant improved PFS in 1L HR+ breast cancer

First and only next-generation oral SERD and complete ER antagonist to demonstrate 1st-line benefit in combination with widely approved CDK4...

Cision • 26 Feb 08:03

Filing of Annual Report on Form 20-F with the US Securities and Exchange Commission

Cision • 19 Feb 08:12

Annual Financial Report

Cision • 18 Feb 12:00

Non-Executive Board Changes

Cision • 18 Feb 08:03

Imfinzi perioperative regimen improved event-free survival and overall survival across muscle-invasive bladder cancer patients regardless of complete pathology response status in NIAGARA trial

Imfinzi reduced the risk of distant metastases and death from bladder cancer vs.

Cision • 14 Feb 17:11

Resultat för helåret och fjärde kvartalet 2024

Cision • 06 Feb 08:00

Imfinzi recommended for approval in the EU by CHMP as first and only immunotherapy for limited-stage small cell lung cancer

Recommendation based on ADRIATIC Phase III trial results which showed a 27% reduction in the risk of death versus placebo.

Cision • 03 Feb 08:00

Enhertu approved in the US as first HER2-directed therapy for patients with HER2-low or HER2-ultralow metastatic breast cancer following disease progression after one or more endocrine therapies

Based on DESTINY-Breast06 Phase III trial results which showed Enhertu demonstrated superiority vs.

Cision • 28 Jan 08:00

AstraZeneca plans C$820 million (US$570m) investment in Canada to advance growing global hub and clinical delivery

700 new scientific and high-skilled jobs to be created in Greater Toronto Area, investing to execute more than 210 AstraZeneca global clinic...

Cision • 23 Jan 20:15

Datroway (datopotamab deruxtecan) approved in the US for patients with previously treated metastatic HR-positive, HER2-negative breast cancer

First approval in the US for AstraZeneca and Daiichi Sankyo’s Datroway based on TROPION-Breast01 results showing 37% reduction in the risk o...

Cision • 20 Jan 08:00

Calquence plus chemoimmunotherapy approved in the US for patients with previously untreated mantle cell lymphoma

Based on ECHO Phase III trial results which showed more than 16 months of progression-free survival improvement vs.

Cision • 17 Jan 08:02

Datopotamab deruxtecan granted Priority Review in the US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer

Application based on TROPION-Lung05 trial and supported by data from TROPION-Lung01 and TROPION-PanTumor01 trials.

Cision • 13 Jan 08:05

Datopotamab deruxtecan application in the EU for patients with advanced nonsquamous non-small cell lung cancer voluntarily withdrawn

Cision • 24 Dec 2024 08:01

Tagrisso approved in the EU for patients with unresectable EGFR-mutated lung cancer

First and only EGFR inhibitor and targeted treatment approved in the EU in unresectable NSCLC.

Cision • 23 Dec 2024 08:00

Non-Executive Board Appointments

Cision • 16 Dec 2024 09:22

Lynparza demonstrated clinically meaningful prolonged survival benefit in early breast cancer in OlympiA Phase III trial

87.5% of patients treated with Lynparza were alive at six years vs.

Cision • 11 Dec 2024 17:07

Datopotamab deruxtecan granted breakthrough therapy designation in US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer

First Breakthrough Therapy Designation for AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan.

Cision • 09 Dec 2024 08:00

Fixed-duration Calquence plus venetoclax demonstrated superior PFS vs. standard of care in previously untreated CLL, with 77% of patients progression free at three years in AMPLIFY Phase III trial

Calquence plus venetoclax with obinutuzumab reduced the risk of disease progression or death by 58% versus standard of care in this setting.

Cision • 08 Dec 2024 17:00

Imfinzi granted Priority Review in the US for patients with muscle-invasive bladder cancer

Decision based on NIAGARA Phase III trial results which demonstrated a statistically significant and clinically meaningful event-free and ov...

Cision • 06 Dec 2024 08:00

Imfinzi approved in the US as first and only immunotherapy regimen for patients with limited-stage small cell lung cancer

Based on ADRIATIC Phase III trial results which showed a 27% reduction in the risk of death versus placebo.

Cision • 05 Dec 2024 08:00

AstraZeneca appoints Iskra Reic as Executive Vice President, International

Cision • 04 Dec 2024 14:45

Truqap improved rPFS in advanced prostate cancer

First and only AKT inhibitor combination to demonstrate benefit in this specific subtype of prostate cancer.

Cision • 25 Nov 2024 08:00

Tagrisso recommended for approval in the EU by CHMP for patients with unresectable EGFR-mutated lung cancer

Recommendation based on LAURA Phase III trial results which showed Tagrisso extended median progression-free survival to more than three yea...

Cision • 18 Nov 2024 08:00

AstraZeneca invests $3.5 billion in R&D and manufacturing in the United States

Cision • 12 Nov 2024 08:10

Koselugo showed statistically significant and clinically meaningful objective response rate vs. placebo in adults with neurofibromatosis type 1 in global KOMET Phase III trial

Results demonstrated reduction in tumour volume, building on established safety and efficacy profile of Koselugo in children and supporting ...

Cision • 12 Nov 2024 08:05